这家中国抗癌药明星企业交出了史上首份盈利年报,但高达612亿元的累计未弥补亏损、对单一产品的深度依赖,以及愈演愈烈的中美药品定价博弈,令其“全球肿瘤创新公司”的故事蒙上阴影。 对百济神州而言,2025年本应是举杯相庆的一年。 这家同时在纳斯达克、港交所和上交所科创板挂牌的生物科技企业,全年营业收入同比增长40.46%至382.25亿元,归母净利润录得14.61亿元——这是公司自2010年成立...
Source Link这家中国抗癌药明星企业交出了史上首份盈利年报,但高达612亿元的累计未弥补亏损、对单一产品的深度依赖,以及愈演愈烈的中美药品定价博弈,令其“全球肿瘤创新公司”的故事蒙上阴影。 对百济神州而言,2025年本应是举杯相庆的一年。 这家同时在纳斯达克、港交所和上交所科创板挂牌的生物科技企业,全年营业收入同比增长40.46%至382.25亿元,归母净利润录得14.61亿元——这是公司自2010年成立...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.